- Report
- April 2024
- 316 Pages
Global
From €6794EUR$6,995USD£5,804GBP
- Report
- October 2023
- 193 Pages
Global
From €4371EUR$4,500USD£3,734GBP
- Report
- August 2022
- 193 Pages
Global
From €2380EUR$2,450USD£2,033GBP
- Report
- June 2023
- 100 Pages
Canada
From €3836EUR$3,950USD£3,278GBP
- Report
- November 2022
- 110 Pages
Global
From €5779EUR$5,950USD£4,937GBP
The Latent Tuberculosis Testing market is a subset of the larger Infectious Disease Testing market. It is used to detect the presence of Mycobacterium tuberculosis, the bacteria that causes tuberculosis, in individuals who may not show any symptoms of the disease. Tests used in this market include the tuberculin skin test, interferon-gamma release assays, and nucleic acid amplification tests. These tests are used to diagnose latent tuberculosis infection, which is when the bacteria is present in the body but is not causing any symptoms.
The Latent Tuberculosis Testing market is driven by the increasing prevalence of tuberculosis, the availability of new testing technologies, and the growing awareness of the disease. Governments and healthcare organizations are investing in the development of new tests and treatments to reduce the burden of tuberculosis.
Some companies in the Latent Tuberculosis Testing market include Abbott, Becton Dickinson, Cepheid, Hologic, and Qiagen. Show Less Read more